Clearmind Medicine Announces It Is In Compliance With All Applicable Nasdaq Listing Standards
Portfolio Pulse from Benzinga Newsdesk
Clearmind Medicine Inc. (CMND) has regained compliance with Nasdaq's minimum bid price requirement, with its common shares maintaining a bid price of $1.00 or greater for 10 consecutive business days. Nasdaq has closed the prior bid price deficiency matter, and the company's scheduled hearing with the Nasdaq Listing Qualifications Hearings Panel has been canceled. Clearmind's common shares will continue to be listed and traded on Nasdaq.
December 14, 2023 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearmind Medicine Inc. has resolved its bid price deficiency with Nasdaq, ensuring continued listing and trading of its common shares on the exchange.
Regaining compliance with Nasdaq's listing requirements removes the immediate risk of delisting, which is a positive development for the company and its investors. This news is likely to be viewed favorably by the market, potentially leading to increased investor confidence and a positive short term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100